Paradigm Biocapital Advisors LP

Position in TARS — Tarsus Pharmaceuticals, Inc.

CIK 1855655 NEW YORK, NY

Position in TARS

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$174,699,348

-$5,035,755 QoQ

Shares Held

2,775,649

+8.3% QoQ

Ownership

6.33%

of shares outstanding

% of Portfolio

3.79%

of 13F equity value

Holder Rank

of 256 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Paradigm Biocapital Advisors LP holds $4,608,890,546 across 28 Biotechnology names. TARS ranks #10 (3.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	6,361,323	$1,191,348,571
2	EWTX	Edgewise Therapeutics, Inc.	10,215,455	$415,053,936
3	GMAB	Genmab A/S	13,133,131	$360,767,108
4	SYRE	Spyre Therapeutics, Inc.	3,840,778	$340,984,270
5	APGE	Apogee Therapeutics, Inc.	1,576,385	$209,233,581
6	ORKA	Oruka Therapeutics, Inc.	2,144,526	$204,094,539
7	TNGX	Tango Therapeutics, Inc.	6,357,523	$198,736,168
8	BLTE	Belite Bio, Inc	1,232,877	$189,844,564

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$174,699,348	2,775,649	+8.3%	Shares	Sole	2026-08-14
2026-03-31	$179,735,103	2,562,154	0.0%	Shares	Sole	2026-05-15
2025-12-31	$209,789,169	2,562,154	-3.9%	Shares	Sole	2026-02-17
2025-09-30	$158,422,432	2,665,698	-10.4%	Shares	Sole	2025-11-14
2025-06-30	$120,561,770	2,976,099	+14.0%	Shares	Sole	2025-08-14
2025-03-31	$134,085,819	2,610,197	+3.1%	Shares	Sole	2025-05-15
2024-12-31	$140,191,081	2,531,896	+3.7%	Shares	Sole	2025-02-14
2024-09-30	$80,266,236	2,440,445	+0.2%	Shares	Sole	2024-11-14
2024-06-30	$66,194,606	2,435,416	-14.9%	Shares	Sole	2024-08-14
2024-03-31	$104,084,808	2,863,406	+179.4%	Shares	Sole	2024-05-15
2023-12-31	$20,756,250	1,025,000	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.